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A B S T R A C T
Background
The diagnosis of bronchiectasis is defined by abnormal dilation of the airways related to a pathological mechanism of progressive airway
destruction that is due to a ’vicious cycle’ of recurrent bacterial infection, inflammatory mediator release, airway damage, and subsequent
further infection. Antibiotics are the main treatment option for reducing bacterial burden in people with exacerbations of bronchiectasis
and for longer-term eradication, but their use is tempered against potential adverse effects and concerns regarding antibiotic resistance.
The comparative effectiveness, cost-effectiveness, and safety of different antibiotics have been highlighted as important issues, but
currently little evidence is available to help resolve uncertainty on these questions.
Objectives
To evaluate the comparative effects of different antibiotics in the treatment of adults and children with bronchiectasis.
Search methods
We identified randomised controlled trials (RCTs) through searches of the Cochrane Airways Group Register of trials and online trials
registries, run 30 April 2018. We augmented these with searches of the reference lists of published studies.
Selection criteria
We included RCTs reported as full-text articles, those published as abstracts only, and unpublished data. We included adults and
children (younger than 18 years) with a diagnosis of bronchiectasis by bronchography or high-resolution computed tomography who
reported daily signs and symptoms, such as cough, sputum production, or haemoptysis, and those with recurrent episodes of chest
infection; we included studies that compared one antibiotic versus another when they were administered by the same delivery method.
Data collection and analysis
Two review authors independently assessed trial selection, data extraction, and risk of bias. We assessed overall quality of the evidence
using GRADE criteria. We made efforts to collect missing data from trial authors. We have presented results with their 95% confidence
intervals (CIs) as mean differences (MDs) or odds ratios (ORs).
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Main results
Four randomised trials were eligible for inclusion in this systematic review - two studies with 83 adults comparing fluoroquinolones
with β-lactams and two studies with 55 adults comparing aminoglycosides with polymyxins.
None of the included studies reported information on exacerbations - one of our primary outcomes. Included studies reported no serious
adverse events - another of our primary outcomes - and no deaths. We graded this evidence as low or very low quality. Included studies
did not report quality of life. Comparison between fluoroquinolones and β-lactams (amoxicillin) showed fewer treatment failures in
the fluoroquinolone group than in the amoxicillin group (OR 0.07, 95% CI 0.01 to 0.32; low-quality evidence) after 7 to 10 days of
therapy. Researchers reported that Pseudomonas aeruginosa infection was eradicated in more participants treated with fluoroquinolones
(Peto OR 20.09, 95% CI 2.83 to 142.59; low-quality evidence) but provided no evidence of differences in the numbers of participants
showing improvement in sputum purulence (OR 2.35, 95% CI 0.96 to 5.72; very low-quality evidence). Study authors presented no
evidence of benefit in relation to forced expiratory volume in one second (FEV ). The two studies that compared polymyxins versus
aminoglycosides described no clear differences between groups in the proportion of participants with P aeruginosa eradication (OR
1.40. 95% CI 0.36 to 5.35; very low-quality evidence) or improvement in sputum purulence (OR 0.16, 95% CI 0.01 to 3.85; very
low-quality evidence). The evidence for changes in FEV was inconclusive. Two of three trials reported adverse events but did not
report the proportion of participants experiencing one or more adverse events, so we were unable to interpret the information.
Authors’ conclusions
Limited low-quality evidence favours short-term oral fluoroquinolones over beta-lactam antibiotics for patients hospitalised with
exacerbations. Very low-quality evidence suggests no benefit from inhaled aminoglycosides verus polymyxins. RCTs have presented
no evidence comparing other modes of delivery for each of these comparisons, and no RCTs have included children. Overall, current
evidence from a limited number of head-to-head trials in adults or children with bronchiectasis is insufficient to guide the selection of
antibiotics for short-term or long-term therapy. More research on this topic is needed.
P L A I N L A N G U A G E S U M M A R Y
How do different antibiotics compare in terms of safety and treatment effectiveness for people with bronchiectasis?
Background
Bronchiectasis is defined as abnormal widening of the airways in the lungs. It is usually caused by repeated bacterial chest infections,
which damage the airways. Antibiotics are the main option for treating these infections and are used to prevent repeated infections
over the longer term. However, use of antibiotics must be weighed against potential side effects and concerns over the development
of bacterial resistance to treatment with antibiotics that reduces their effectiveness. Only a small number of studies have focused on
antibiotics for people with bronchiectasis. Further clarity about how different antibiotics compare with one another is urgently needed.
Study characteristics
In April 2018, we looked for studies including adults or children with bronchiectasis that randomly allocated participants to receive
one antibiotic or another by the same method of administration. We found only four studies, and they were very small. In total, they
included 138 participants. This small sample makes it very difficult to draw clear conclusions.
Key results
Four randomised trialswere eligible for inclusion in this systematic review.None of the included studies reported informationonflare-ups
(exacerbations). Included studies reported no deaths and no serious adverse events. Treatment failures were fewer with fluoroquinolone
antibiotics than with amoxicillin antibiotics.
Quality of the evidence
Reviewers considered the quality of the evidence provided by the four small included studies to be low or very low.
Key message
Fluoroquinolone antibiotics may be more successful than amoxicillin antibiotics in treating exacerbations, but this finding is based on
low-quality evidence. More evidence from high-quality clinical trials of short-term and long-term treatment with antibiotics is needed
if clear conclusions are to be reached on the benefits of one antibiotic over another for people with bronchiectasis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fluoroquinolones compared to amoxicillin for bronchiectasis: short- term studies (< 4 weeks)
Patient or population: adults aged 18 years and above with diagnosis of non-cyst ic f ibrosis bronchiectasis
Setting: hospital, Hong Kong
Intervention: f luoroquinolones (Chan 1996: ciprof loxacin, 500 mg, oral, twice daily, 7 days; Lam 1989: of loxacin, 200 mg, oral, thrice daily, 10 days)
Comparison: amoxicillin (Chan 1996: 1000 mg, oral, 3 t imes per day, 7 days; Lam 1989: 1000 mg, oral, 3 t imes per day, 10 days)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with amoxicillin Risk with fluoro-
quinolones
Exacerbat ions - - Not est imable - - Outcome not reported in
included studies
Serious adverse events 0 per 1000 0 per 1000
(0 to 0)
Not est imable 83
(2 RCTs)
⊕⊕©©
LOWa,b
Evidence graded on the
overall quality of the study
Response rate - treat-
ment failure
429 per 1000 50 per 1000
(7 to 194)
OR 0.07
(0.01 to 0.32)
83
(2 RCTs)
⊕⊕©©
LOWa,b
Response rate - m icro-
biological response
2 out of 8 part icipants
responded.
8 out of 8 part icipants
responded.
Peto OR 20.09 (2.83 to
142.59)
16
(1 RCT)
⊕⊕©©
LOWa,b
Small single study. PetoOR
used owing to 100% re-
sponse in intervention arm
Response rate - im-
provement in sputum
purulence (excellent)
357 per 1000 566 per 1000
(348 to 761)
OR 2.35
(0.96 to 5.72)
83
(2 RCTs)
⊕©©©
VERY LOWa,b,c
Deaths 0 per 1000 0 per 1000
(0 to 0)
Not est imable 83
(2 RCTs)
⊕⊕©©
LOWa,b
No deaths reported. Evi-
dence graded on the overall
quality of the study
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Quality of lif e - - Not est imable - - Outcome not reported in
included studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOne point deducted in relat ion to design and implementat ion of available studies suggest ing likelihood of bias (unclear
generat ion of randomisat ion sequence, potent ial select ive report ing bias, and risk of other bias in Lam 1989).
bOne point deducted for imprecision (small sample size and few events).
cOne point deducted for imprecision (wide conf idence interval).
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B A C K G R O U N D
Description of the condition
Bronchiectasis is characterised by abnormal dilation of the airways
that is associated with a pathological mechanism of progressive air-
way destruction that is due to the ’vicious cycle’ of recurrent bac-
terial infection, inflammatory mediator release, airway damage,
and subsequent further infection (Cole 1986). The airways show
chronic inflammation with various features, including loss of cili-
ated epithelium and mucous gland hypertrophy. Bacterial coloni-
sation is facilitated by this loss of an integral epithelial structure
(host defence), which, in turn, triggers further immune responses
and continuation of the inflammatory process. An understanding
of this cycle is central to the management of bronchiectasis, as
strategies to arrest both inflammatory and bacterial components
are required to limit the progression of lung injury. Typically mi-
crobiology for patients with bronchiectasis includes Haemophilus
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, and
Pseudomonas aeruginosa, although the microbiological profile of
the latter differs between adults and children, with P aeruginosa
more common in adults and prevalent in only 0% to 6% of chil-
dren. P aeruginosa colonisation often occurs later in the natu-
ral progression of the condition and may infer a worse prognosis
in terms of symptoms, exacerbations, and loss of lung function
(Evans 1996). In severe cases, the cycle of lung infection may lead
to repeated hospitalisations, chronic respiratory failure, and death.
Most adult cases of bronchiectasis are idiopathic or are the result of
a previous severe lung infection. However, treatable causes, such as
immune deficiency, allergic bronchopulmonary aspergillosis, my-
cobacterial infection, and recurrent aspiration, may be identified
in a minority of cases (Goeminne 2012; Pasteur 2010; Wilson
2013). One study found that a proportion of cases were associated
with chronic obstructive pulmonary disease (COPD) and con-
nective tissue diseases (Loni 2015). Underlying causes can be de-
termined in up to 70% of paediatric cases (Eastham 2004; Twiss
2005). Diagnosis is based on a combination of clinical symptoms
and high-resolution computerised tomography (HRCT) showing
one or more abnormally dilated bronchi (Chang 2010; Pasteur
2010). Symptomsmay include chronic productive cough, wheeze,
and breathlessness, together with recurrent lower respiratory tract
infections. One study estimated the prevalence of P aeruginosa
in bronchiectasis to be 15% (Araújo 2018). Colonisation with P
aeruginosa and frequent exacerbations are associated with acceler-
ated decline in lung function (Evans 1996;Martínez García 2007)
and, along with impaired exercise capacity and respiratory symp-
toms, reduced quality of life and increased hospitalisations (Finch
2015; Wilson 1997).
Management of bronchiectasis requires careful attention to spu-
tum clearance, bronchodilator therapy, and the prescription of an-
tibiotics (Welsh 2015). In the short term, the main aim is to re-
duce microbial load to reduce the severity and frequency of exac-
erbations, thereby ameliorating symptoms and improving quality
of life (Pasteur 2010), with the longer-term aim of breaking the
infection cycle, slowing the decline in lung function, and reducing
mortality rates. Antibiotics have traditionally been reserved for the
treatment of acute infection/exacerbation, although prophylactic
strategies may have a role in some cases. Use of macrolides is at-
tracting further interest, and trials have explored their prescription
for patients with bronchiectasis (Wu 2014).
Global prevalence estimates are unclear because of variable diag-
nostic strategies (Weycker 2005), along with higher prevalence
rates in low- and middle-income countries (Habesoglu 2011).
Mortality rates in England andWales rose by 3% per year between
2001 and 2007 (Roberts 2010), and hospitalisations increased by
3% per year over a nine-year period in the USA (Seitz 2010).
Higher prevalence rates were associated with people over 60 years
of age andwith women, and they varied by ethnicity (Chang 2003;
Seitz 2012). Recent data from a UK study suggest that incidence
and prevalence may be higher than previously estimated (Quint
2016). Over a nine-year period to 2013, point prevalence rates per
100,000 rose from 350.5 to 566.1 in women, and from 301.2 to
485.5 in men. This reflects an increase of more than 60%, with
almost 263,000 adults living with bronchiectasis in 2013. Simi-
larly, incidence rates per 100,000 person-years rose from 21.2 to
35.2 in women, and from 18.2 to 26.9 in men, representing an
approximate increase in new cases of 63% to over 15,000 in 2013.
Bronchiectasis is also associatedwith higher age-adjustedmortality
rates, with estimates 2.26 times higher in women and 2.14 times
higher in men compared to the general population (Quint 2016).
The disease has a significant impact on paediatric populations, and
quality of life is worse for younger children and those with a more
frequent annual exacerbation rate (Kapur 2012). Global preva-
lence estimates are variable, ranging from conservative estimates of
17.2 in the North-East of England - as reported in Eastham 2004
- to 33.5 in New Zealand - presented in Twiss 2005 - per 100,000
children under 15 years of age. Rates may be higher in children
from indigenous populations, with estimates of 1 per 625 (160 per
100,000) in children from the Pacific Islands (Twiss 2005), 15 per
1000 (1500 per 100,000) in native central Australian Aborginal
children, and 16 per 1000 (1600 per 100,000) in Native Alaskan
children (Chang 2002; Singleton 2000). However, these increases
in bronchiectasis may reflect improved detection rates through
high-quality computerised tomography (CT) scans, rather than a
true rise in prevalence (Goeminne 2016).
The economic burden of bronchiectasis may be considerable, but
little information is available. Data collected in 2001 in the USA
showed an additional two days in hospital, six more outpatient en-
counters, and 27.2 more days of antibiotic therapy associated with
bronchiectasis (Weycker 2005). Estimates of overall additional an-
nual costs of bronchiectasis range from USD 5681 to USD 7827,
based on data collected between 2001 and 2009 (Joish 2013; Seitz
2010; Weycker 2005).
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Description of the intervention
Bronchiectasis is characterised by daily coughing, sputum expec-
toration, and recurrent respiratory infection. Serial infections of-
ten culminate in bacterial colonisation with dilation and inflam-
mation of the airways. Whilst abnormalities may be pan-lobar (i.e.
throughout both lungs), bronchiectasis may be limited to a single
lung lobe or may manifest in a patchy distribution. Antibiotics are
used to reduce bacterial burden to tackle the cycle of infection and
tissue damage (Cole 1984; Pasteur 2010). They may be admin-
istered on a short-term basis (less than four weeks) to treat acute
exacerbations, or over a longer-term (≥ four weeks). Longer du-
rations of antibiotics are used to eradicate pathogens, to suppress
bacterial load, or to enhance anti-inflammatory properties (e.g.
macrolides). Several routes of administration are available, includ-
ing oral, inhaled, and parenteral routes, with analysis of sputum
bacteriology informing the specific choice of antibiotic (Polverino
2017). Prescribing is also informed by clinical context, and bacte-
riology and sputum purulence are considered reliable indicators of
the need for treatment (Hill 1988). Antibiotics may therefore be
prescribed before the results of sputum bacteriology are obtained.
Antibiotics are a frontline therapy for the management of bacterial
load in bronchiectasis, but their use is tempered against adverse
effects and increasing concerns over antibiotic resistance (Pasteur
2010).
How the intervention might work
A range of antibiotic strategies have been used to reduce bacterial
load and re-infection rates in people with bronchiectasis, including
short-term prescriptions for acute exacerbations and longer-term
prophylactic use for frequent exacerbations in which chronic spu-
tumpurulence is a common feature (Chalmers 2012; Evans 2003).
Longer-term use of antibiotics is not currently recommended as
part of routine treatment (Valery 2012; Wu 2014), but it may be
considered for patients with frequent exacerbations (three or more
per year requiring antibiotic therapy) (Pasteur 2010). Antibiotic
choice is usually guided by sputum microbiology and patterns of
local antibiotic resistance, but treatment is often started empiri-
cally with a broad-spectrum oral or intravenous antibiotic until
the specific pathogen has been isolated (Pasteur 2010). If more
than one culture is positive, an antibiotic is selected to cover both.
Macrolide antibiotics may be prescribed for their potential anti-
inflammatory properties as well as for their antibacterial effects.
Why it is important to do this review
Evidence for the effectiveness of a range of treatment strategies
in bronchiectasis is limited by the number and quality of clinical
trials, including those on antibiotics, and the need for evidence
based on head-to-head comparisons of antibiotics has been high-
lighted as a key priority (Welsh 2015). The comparative effective-
ness, cost-effectiveness, and safety of within-class antibiotics (e.g.
from different manufacturers) remain unclear, but this type of ev-
idence could be used to inform choice of antibiotic, particularly
in developing countries, where use of cheaper antibiotics may be
more prevalent than in developed countries.
Therefore this Cochrane Review will include studies that directly
compare the effectiveness of antibiotics and consider issues related
to duration of treatment and mode of delivery. We will endeavour
to draw together existing evidence showing their effectiveness for
bronchiectasis against key outcomes identified by Welsh 2015.
We are conducting this as a Cochrane Review and are employing
established methods in accordance with the recent evaluation of
these standards versus alternative approaches (Page 2016). This
Cochrane Review is being conducted alongside four other closely
related reviews: “Macrolide antibiotics for bronchiectasis” (Kelly
2018); “Dual antibiotics for bronchiectasis” (Felix 2018); “Oral
versus inhaled antibiotics for bronchiectasis” (Spencer 2018); and
“Continuous versus intermittent antibiotics for bronchiectasis”
(Donovan 2018).
O B J E C T I V E S
To evaluate the comparative effects of different antibiotics in the
treatment of adults and children with bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported as full-text articles, those published as abstracts
only, and unpublished data.
Types of participants
We included adults and children (less than 18 years of age) with a
diagnosis of bronchiectasis by bronchography or high-resolution
computed tomography who reported daily signs and symptoms,
such as cough, sputumproduction, or haemoptysis, and those with
recurrent episodes of chest infection.We excluded studies inwhich
patients received continuous or high-dose antibiotics during the
four weeks before the start of the study, if they had received a
diagnosis of traction bronchiectasis due to pulmonary fibrosis, or
if they had received a diagnosis of cystic fibrosis.
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Types of interventions
We included studies that compared one antibiotic versus another
when they were administered by the same delivery method (e.g.
nebulised vs nebulised) to isolate the effect of the antibiotic rather
than the delivery device. We considered short-term use (less than
four weeks) for treating acute exacerbations and longer-term use
as a prophylactic (≥ four weeks) separately. We also planned to
analyse generational comparisons (e.g. third- vs fourth-generation
fluoroquinolones) separately frombetween-class comparisons (e.g.
penicillin vs fluoroquinolones).
Types of outcome measures
Primary outcomes
We included the following primary outcomes.
1. Exacerbation (e.g. frequency during follow-up, time to first
exacerbation).
2. Serious adverse events, defined according to Hansen 2015.
Secondary outcomes
We included the following secondary outcomes for both short-
and long-term therapy.
1. Frequency of hospitalisations due to exacerbations of
bronchiectasis.
2. Response rates as defined by study authors (e.g. diary cards
of physician global assessment).
3. Sputum volume and purulence.
4. Measures of lung function (e.g. forced expiratory volume in
one second (FEV )).
5. Systemic markers of infection (e.g. leucocyte count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR)).
6. Adverse events (e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment).
7. Deaths, all-cause and respiratory.
8. Emergence of resistance to antibiotics.
9. Exercise capacity (e.g. six-minute walk distance (6MWD)).
10. Quality of life (e.g. St George Respiratory Questionnaire
(SGRQ), QoL-B).
Reporting one or more of the outcomes listed here was not an
inclusion criterion for studies in this Cochrane Review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), in the Cochrane Library,
through the Cochrane Register of Studies Online
(crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date.
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine).
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. We have
provided details of these strategies, as well as a list of handsearched
conference proceedings, in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We also conducted
a search of ClinicalTrials.gov (www.ClinicalTrials.gov), as well as
the World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) portal ( www.who.int/ictrp/
en/). We searched all databases from their inception to 30 April
2018, and we imposed no restriction on publication language.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We also searched relevant man-
ufacturers’ websites for trial information.
We searched for errata or retractions from included studies
published in full text on PubMed on 30 November 2017 (
www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (ES and LF) independently screened titles and
abstracts of all studies identified by the literature search and coded
them as ’retrieve’ (eligible or potentially eligible/unclear studies) or
’do not retrieve’. We retrieved the full-text study reports/publica-
tions for all articles in the ’retrieve’ category. The same review au-
thors independently screened the full-text articles, identified stud-
ies for inclusion, and identified and recorded reasons for exclusion
of ineligible studies. We resolved disagreements through discus-
sion and consulted a third review author (SJM) to clarify the in-
clusion of two similar reports. We planned to identify and exclude
duplicates and to collate multiple reports of the same study, so that
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each study rather than each report was the unit of interest in the
review. We recorded the selection process in detail in a PRISMA
flow diagram and in the Characteristics of excluded studies tables
(Moher 2009).
Data extraction and management
We used a data collection form that was pilot-tested on one in-
cluded study to record study characteristics and outcome data.
One review author (LF) extracted the following characteristics
from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
settings, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (AK and LF) independently extracted
outcome data from the included studies and noted in the
Characteristics of included studies table when outcome data were
not reported in a usable way. We resolved disagreements by con-
sensus or by consultation with a third review author (SS or SJM).
One review author (LF) transferred data into Review Manager 5
(RevMan 5) (Review Manager 2014), and a second review author
(AK) verified the data by spot-checking study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (AK and LF) independently assessed the risk
of bias for each included study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).We resolved disagreements by discussion or by consultation
with another review author (SS or SJM). We assessed risk of bias
according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
’Risk of bias’ judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for a
patient-reported pain scale).When information on risk of bias was
related to unpublished data or correspondence with a trial author,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to the outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
(Kaehne 2017), and we reported deviations from it in the Differ-
ences between protocol and review section of the systematic re-
view.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean differences or standardised mean differences. We entered
data presented as a scale with a consistent direction of effect.
We planned to undertake meta-analyses only when this was mean-
ingful (i.e. if treatments, participants, and the underlying clinical
question were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
When a single trial had multiple trial arms, we included only
relevant trial arms. If two comparisons (e.g. drug A vs drug B and
drug C vs drug B) were combined in the same meta-analysis, we
planned to halve the comparison group to avoid double-counting.
Unit of analysis issues
In all included studies, the unit of analysis was the participant.
We planned to analyse exacerbation rates as rate ratios if data had
been available.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as abstract only).
When this was not possible, and we believed that the missing data
may have introduced serious bias, we planned to explore the im-
pact of including such studies in the overall assessment of results
by performing a sensitivity analysis.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the trials in each meta-analysis. When we identified substantial
heterogeneity (i.e. I² > 50%) (Deeks 2011), we reported this and
explored possible causes by conducting pre-specified subgroup
analysis.
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Assessment of reporting biases
If we had pooled more than 10 studies, we planned to create and
examine a funnel plot to explore possible small-study effects and
evidence of publication bias.
Data synthesis
We planned to use a fixed-effect model for meta-analysis and to
perform sensitivity analyses using a random-effects model.
’Summary of findings’ table
We created a ’Summary of findings’ table using the following
primary and secondary outcomes: exacerbations, serious adverse
events, response rates, deaths, and quality of life.We used the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of evidence from studies contributing data to meta-analyses of
pre-specified outcomes. We used methods and recommendations
described in Section 8.5 - in Higgins 2011 - and in Chapter 12
- Schünemann 2011 - of the Cochrane Handbook for Systematic
Reviews of Interventions using GRADEpro software (GRADEpro
GDT). We provided justification for our decisions to downgrade
or upgrade the quality of studies by using footnotes and made
comments to aid the reader’s understanding of the Cochrane Re-
view when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Adults versus children.
2. Dose or schedule, or both.
3. Duration (prophylactic antibiotics).
4. Type of antibiotic.
We planned to use the following outcomes in subgroup analyses.
1. Exacerbation duration (short-term therapy).
2. Exacerbation frequency (long-term therapy).
3. Hospitalisation.
4. Adverse events.
We planned to use the formal test for subgroup interactions in
RevMan 5 (Review Manager 2014).
Sensitivity analysis
If we had found sufficient studies, we planned to evaluate the im-
pact of methodological study quality by removing studies at high
or unclear risk of bias according to the following risk of bias do-
mains: random sequence generation and allocation concealment.
We planned to use a fixed-effect model, as well as a random-effects
model, in performing our sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
A systematic search, conducted on 30 April 2018, identified 295
unique records of potentially relevant studies. Of these, we consid-
ered 262 records irrelevant following inspection of their titles and
abstracts. We obtained the full texts of the remaining 33 records
and scrutinised them for selection. Four studies met the Review
selection criteria (Lam 1989; Chan 1996; Dimakou 2014; Kaponi
2017), and we included them in the Review (see Characteristics of
included studies); we formally excluded 26 records (documented
in Excluded studies). Two records were protocols for an ongoing
study - Chang 2013 (documented in Characteristics of ongoing
studies), and for one study that is awaiting classification - Lam
1986 - as we could not ascertain whether it is a separate study
fromLam1989 (documented inCharacteristics of studies awaiting
classification). We have summarised the study selection process in
the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Methods
All four included studies were reported as RCTs (Chan 1996;
Dimakou 2014; Kaponi 2017; Lam 1989). Two studies were
two-arm, double-blind, placebo-controlled trials using a double-
dummy design, each conducted at a single centre in Hong Kong
(Chan 1996; Lam 1989). Dimakou 2014 was a three-arm (to-
bramycin vs colistin vs saline) trial, and Kaponi 2017 was also a
three-arm trial (tobramycin vs colistin vs placebo). Both studies
were available only as conference abstracts and did not report study
details such as design methods, study setting, or methods of par-
ticipant recruitment. We contacted trial authors for further infor-
mation, but at the time of publication, we have received no reply.
Both Chan 1996 and Lam 1989 worked with patients admitted
to the hospital. Chan 1996 reported no withdrawals. No patients
withdrew from Lam 1989, although therapy was suspended for
two patients with adverse reactions to the intervention. No pa-
tients withdrew from Dimakou 2014 or Kaponi 2017.
Participants
The four studies included a total of 164 adults, aged 18 years
and older. Dimakou 2014 was a three-arm study that included
a placebo group with nine control group participants. Kaponi
2017 was a three-arm study that included a placebo group of 17
participants. Therefore 138 participants were eligible for inclusion
in the Review. Two studies based a diagnosis of bronchiectasis
on clinical and radiological criteria (Chan 1996; Lam 1989), but
diagnostic criteria in Dimakou 2014 were unclear. Chan 1996
and Lam 1989 included participants hospitalised with infective
exacerbation of bronchiectasis, confirmed by sputum purulence or
volume. Dimakou 2014 and Kaponi 2017 included participants
with sputum cultures with > 10 colony-forming units (CFUs)
of P aeruginosa per millilitre. Of the three studies that reported
gender, 64% of participants in Chan 1996 (F 27; M 42), 44% in
Lam 1989 (F 18; M 23), and 63% in Kaponi 2017 (F 33; M 19)
were female. The mean age of participants was 64 years in Chan
1996; 56 years in Dimakou 2014; 53 years in Lam 1989; and 59
years in Kaponi 2017, representing a total age range of 22 to 74
years.
Two studies reported that data showed no baseline imbalances
between intervention groups (Chan 1996; Lam 1989). Chan 1996
reported a mean baseline FEV of 69%, and Lam 1989 91%, of
predicted.
Two studies reported smoking history, with non-smokers repre-
senting 62% of participants in Chan 1996 and 48% in Lam 1989.
In Chan 1996, one participant in the ciprofloxacin group was a
current smoker and 15 were former smokers (six ciprofloxacin,
nine amoxicillin). In Lam 1989, two participants in each of the in-
tervention groups were current smokers, and a total of 17 were for-
mer smokers (eight ofloxacin, nine amoxicillin). Dimakou 2014
and Kaponi 2017 did not provide data on smoking history.
Interventions
Researchers compared the following two types of antibiotics: flu-
oroquinolone versus β-lactam in Chan 1996 and Lam 1989, and
aminoglycoside versus polymyxin in Dimakou 2014 and Kaponi
2017. The two fluoroquinolone versus β-lactam studies delivered
antibiotics orally (Chan 1996; Lam 1989), and the two amino-
glycoside versus polymyxin studies by inhalation (Dimakou 2014;
Kaponi 2017). Studies also differed by duration, with antibiotics
administered for seven and 10 days (Chan 1996; Lam 1989), re-
spectively, in the two short-term studies, and for four weeks and
three months (Dimakou 2014; Kaponi 2017), respectively, in the
two long-term studies.
Table 1 shows the characteristics of interventions in each study
including numbers of participants, types of antibiotics, and dose,
duration, and frequency of administration.
Outcomes
Primary outcomes
Exacerbation
The included studies did not report this outcome.
Serious adverse events
None of the included studies formerly reported serious adverse
events, but these are implied from the reporting of adverse events.
Secondary outcomes
Response rate - treatment failure
Chan 1996 defined treatment failure as ’poor’ improvement in
sputum purulence (assessed at day 7).
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Response rate - microbiological response
Chan 1996 reportedmicrobiological response, defined as elimina-
tion of bacterial organisms amongst those who tested positive for
bacteriological culture at day 0. This was assessed on day 7. Kaponi
2017 defined microbiological response rate as the proportion of
participants in each group showing eradication of P aeruginosa at
the end of treatment.
Response rate - improvement in sputum purulence
Three included studies reported this outcome (Chan 1996;
Dimakou 2014; Lam 1989). Both Chan 1996 and Lam 1989 cat-
egorised improvement in sputum purulence as follows: excellent
- mucoid; fair - pale yellow or pale green; and poor - dark green
or dark yellow. Chan 1996 assessed improvement from baseline at
day 7, and Lam 1989 at day 10. In addition, Lam 1989 assessed
relapse of sputum purulence at three-month follow-up in partici-
pants classified as excellent or fair at 10 days. Dimakou 2014 did
not include classification of sputum purulence.
Sputum volume
All four studies reported sputum volume (Chan 1996; Dimakou
2014; Kaponi 2017; Lam 1989). Chan 1996 reported changes
in sputum volume between baseline and follow-up at five and 10
days. Lam 1989 reported changes between baseline and seven days.
Dimakou 2014 and Kaponi 2017 measured changes in sputum
volume before and after treatment but did not report further de-
tails and direct comparisons between intervention groups in the
abstracts.
Measures of lung function
Lam 1989 reported improvement in FEV % predicted on day
10. Chan 1996 reported FEV % predicted and FEV /forced
vital capacity (FVC) % predicted only at baseline. Dimakou 2014
and Kaponi 2017 measured changes in spirometry before and after
treatment but did not include further details and comparisons
between intervention groups in the abstracts.
Adverse events
Three studies reported this outcome (Chan 1996; Dimakou 2014;
Lam 1989). Both Chan 1996 and Lam 1989 reported the fre-
quency of event types by group and did not report the proportion
of participants in each group who experienced at least one adverse
event. Dimakou 2014 reported the number of participants with
adverse events but did not include further details in the abstract.
Kaponi 2017 did not report adverse events.
Deaths
The four included studies did not formally report this outcome,
but it was inferred based on the number of participants who com-
pleted each study.
Frequency of hospitalisations due to exacerbations of
bronchiectasis; systemic markers of infection: C-reactive
protein (CRP); emergence of resistance to antibiotics; exercise
capacity; quality of life
None of the included studies reported any of the above secondary
outcomes.
Notes
Only two studies provided information about the source of study
funding (Chan 1996; Lam 1989). Both reported that Daiichi
Seiyaku Co Ltd provided active and dummy placebo tablets for
the intervention groups. No included studies provided other in-
formation such as power calculations and declarations of conflicts
of interest.
Excluded studies
We recorded in Characteristics of excluded studies reasons for
exclusion of 26 studies from the 287 reports. We excluded 11
studies of mixed populations because data were not available for
bronchiectasis participants alone (Begg 2000; Brambilla 1992;
Finegold 1981; Garcia-Rodriguez 1984; Jia 2010; Kobayashi
1984; Nakamura 2007; Pines 1964; Pines 1967; Pines 1981;
Ramer 1981). Eight studies were not head-to-head compar-
isons of antibiotics using the same mode of delivery (Alberto
1968; Allen 1988; Bevilacqua 1973; Bilton 2006; Ip 1998; Liu
2012; NCT03093974; NCT03058718). Three studies did not
include bronchiectasis participants (Khan 2003; Kobayashi 1984;
Kobbernagel 2016), a further three studies were not randomised
controlled trials (Cherniack 1959; Lioberes 1990; Mehta 1991),
and the intervention in one study was not an antibiotic (Bradley
2011).
We endeavoured to contact study authors for missing data, but at
the time of publication, these data remain unavailable.
Risk of bias in included studies
Two review authors (AK and LF) assessed the risk of bias in each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions.We have presented an overview
of our judgements in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The four included studies did not report information on sequence
generation or allocation concealment. Therefore, we classified the
risk of allocation bias as unclear.
Blinding
Two studies were double-blinded using a double-dummy design
(Lam 1989; Chan 1996); therefore we considered them to be at
low risk of performance bias. Chan 1996 used blinded outcome
assessors, andwe classified this study as having low risk of detection
bias, but Lam 1989 did not report information on outcome as-
sessors, and we judged this study as having unclear risk. Dimakou
2014 and Kaponi 2017 did not report information on blinding
of the intervention or outcome assessments in the abstracts; we
therefore assessed risk of performance and detection bias in these
studies as unclear.
Incomplete outcome data
Two studies assessed all randomised participants at the end of
treatment (Lam 1989; Chan 1996); we judged these studies to
be at low risk of attrition bias. Although Dimakou 2014 and
Kaponi 2017 reported assessment of all participants before and
after treatment, it is not clear whether this was done at the end of
the study. We therefore judged risk of attrition bias as unclear.
Selective reporting
We judged risk of selective reporting to be unclear in all four studies
because pre-specified protocols were not available and therefore
it was not clear whether researchers reported all planned study
outcomes (Chan 1996;Dimakou 2014; Kaponi 2017; Lam1989).
Other potential sources of bias
Researchers in Chan 1996 withdrew amoxicillin from two partic-
ipants who developed a rash but reported no further in terms of
how long treatment was suspended and whether it was restarted.
We therefore judged this study to be at unclear risk of other sources
of bias. The authors of Lam 1989 noted that high levels of H in-
fluenzae, K pneumoniae, and P aeruginosa may be attributable to
previous exposure to ampicillin and other antibiotics; we therefore
judged this study to be at high risk of other bias. Dimakou 2014
and Kaponi 2017 provided insufficient study information in the
abstracts to inform a clear judgement; we therefore classified this
study as being at unclear risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison
Fluoroquinolones compared to amoxicillin for bronchiectasis;
Summary of findings 2Polymyxins compared to aminoglycosides
for bronchiectasis
Fluoroquinolone versus β-lactam (amoxicillin): short-
term studies (< 4 weeks)
Primary outcomes
Exacerbation
The included studies did not report this primary outcome.
Serious adverse events
The two included studies did not explicitly report the number of
participants who had at least one serious adverse event. However,
none of the adverse events reported in Chan 1996 and Lam 1989
were considered serious adverse events and no randomised partic-
ipants withdrew; we therefore concluded that no serious adverse
events occurred in these two studies.
According to GRADE criteria, we judged this evidence as low
quality.
Secondary outcomes
Response rate - treatment failure
Two studies with 83 adults reported sputum purulence using the
same classification criteria of excellent, fair, and poor (Chan 1996;
Lam 1989). Chan 1996 defined treatment failures as those with
poor improvement after seven days of oral treatment, and we used
this definition of treatment failure for the two studies. The pooled
analysis showed clear differences between groups in the numbers
of participants with poor improvement in sputum purulence, with
significantly fewer treatment failures in the fluoroquinolone group
than in the group receiving amoxicillin (odds ratio (OR) 0.07,
95% confidence interval (CI) 0.01 to 0.32; Analysis 1.1).
According to GRADE criteria, we judged this evidence as low
quality.
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Response rate - microbiological response
One study with 42 adults reported elimination of bacterial organ-
isms inmore participants receiving seven days’ oral treatment with
ciprofloxacin versus seven days’ oral treatment with amoxicillin
(Peto OR 20.09, 95% CI 2.83 to 142.59; Analysis 1.2), although
the effect estimate was based on only 16 participants who tested
positive following baseline sputum culture (Chan 1996).
According to GRADE criteria, we judged this evidence as low
quality.
Response rate - improvement in sputum purulence
Two studies with 83 adults reported no clear differences between
groups in the number of participants with excellent improvement
in sputum purulence (OR 2.35, 95% CI 0.96 to 5.72; Analysis
1.3) (Chan 1996; Lam 1989). According to GRADE criteria, we
judged this evidence as very low quality. The same studies reported
no differences in the number of participants with fair improve-
ment in sputum purulence (OR 2.30, 95% CI 0.88 to 6.00; I² =
53%; Analysis 1.4). We noted substantial heterogeneity between
studies but no clear evidence of subgroup differences (test for sub-
group differences: Chi² = 2.12, df = 1 (P = 0.15), I² = 52.9%).
Separate analysis of the two studies indicated a greater proportion
of participants with fair improvement after seven days’ oral treat-
ment with ciprofloxacin versus seven days’ oral treatment with
amoxicillin (OR 4.67, 95% CI 1.17 to 18.69; Analysis 1.4). Data
show no differences between participants after 10 days’ oral treat-
ment with ofloxacin versus amoxicillin (OR 1.07, 95% CI 0.26
to 4.44; Analysis 1.4).
Relapse of sputum purulence
One study with 41 adults reported relapse of sputum purulence at
three-month follow-up among 32 adults with excellent improve-
ment at the end of treatment (10 days) (Lam 1989). Results
showed no clear difference in relapse of sputumpurulence between
study groups (OR 1.04, 95% CI 0.23 to 4.77; Analysis 1.5).
Sputum volume
A single study with 42 adults reported greater reduction in sputum
volume after seven days’ oral treatment with ciprofloxacin versus
amoxicillin (mean difference (MD) -13.00 mL, 95% CI -18.44
to -7.56; Analysis 1.6) (Chan 1996). Lam 1989 reported more
rapid reduction in sputum volume at day 5 and at day 10 (end of
treatment) in the ofloxacin group than in the amoxicillin group
(P < 0.05), but these study authors did not report mean values for
each group.
Measures of lung function
One study with 41 adult participants reported no clear differences
between groups in the change in FEV %predicted frombaseline
to end of treatment (10 days) (MD -2.70, 95%CI -17.01 to 11.61;
Analysis 1.7) (Lam 1989).
Adverse events
Chan 1996 and Lam 1989 did not report the number of par-
ticipants who experienced at least one adverse event. Chan 1996
reported the frequency of each adverse event as follows: gastroin-
testinal upset: 0 ciprofloxacin, 2 amoxicillin; dizziness/vertigo: 2
ciprofloxacin, 2 amoxicillin; headache: 1 ciprofloxacin, 1 amox-
icillin; and rash: 0 ciprofloxacin, 2 amoxicillin. Amoxicillin was
discontinued in the two participants who developed a rash, but
study authors did not report further details. Lam 1989 reported
the frequency of each adverse event as follows: nausea/epigastric
pain: 2 ofloxacin, 5 amoxicillin; dizziness/vertigo: 1 ofloxacin, 1
amoxicillin; and peripheral eosinophilia: 0 ofloxacin, 1 amoxi-
cillin.
Deaths
All randomised participants completed both of the included stud-
ies (Chan 1996; Lam1989); we therefore concluded that no deaths
occurred during these trials.
Based on the overall study, we graded the quality of this evidence
as low.
Fluoroquinolone versus β-lactam (amoxicillin): long-
term studies (≥ four weeks)
We did not find any studies that performed this comparison.
Polymyxins versus aminoglycosides: short-term
studies (< four weeks)
We did not find any studies that performed this comparison.
Polymyxins versus aminoglycosides: long-term studies
(≥ four weeks)
Primary outcomes
Exacerbation
The included studies did not report this primary outcome.
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Serious adverse events
One study with 20 adults reported that six participants who had
adverse events did not require discontinuation of treatment and no
randomised participants withdrew (Dimakou 2014).We therefore
concluded that no serious adverse events occurred after four weeks
of treatment. Kaponi 2017 did not report this outcome.
Based on GRADE criteria, we judged the quality of this evidence
to be very low.
Secondary outcomes
Response rate - improvement in sputum purulence
One study with 20 adults reported no differences between groups
in the number of participants with improvement in sputum pu-
rulence after four weeks of nebulised treatment (OR 0.16, 95%
CI 0.01 to 3.85; Analysis 2.1), although study authors did not
include criteria for improvement in the abstract (Dimakou 2014).
The study reported improvement in sputum purulence in all 10
participants receiving nebulised colistin compared with eight out
of 10 participants receiving nebulised tobramycin for 4 weeks.
According to GRADE criteria, we judged this evidence as very low
quality.
Response rate - P aeruginosa eradication
Kaponi 2017 reported no differences between groups in terms
of the number of participants with P aeruginosa eradication after
three months of nebulised treatment (OR 1.40. 95% CI 0.36 to
5.35; Analysis 2.2). This study reported that P aeruginosa had been
eradicated in 47% of 17 participants receiving tobramycin and in
39% of 18 participants receiving colistin.
According to GRADE criteria, we judged this evidence as very low
quality.
Sputum volume
Dimakou 2014 reported a significant reduction in sputum volume
among participants receiving nebulised tobramycin (P = 0.005)
and nebulised colistin (P = 0.009) but did not report mean values
and comparisons between study groups in the abstract. Kaponi
2017 reported a reduction in sputum volume of 11.2 mL with to-
bramycin and 11.4 mL with colistin but included direct compar-
isons only for each antibiotic against placebo and did not include
standard deviations in the abstract.
Sputum purulence
Kaponi 2017 reported mean reductions in sputum purulence
scores with each antibiotic compared to placebo but reported no
differences in mean improvement in scores between the group re-
ceiving tobramycin and the group receiving colistin (MD -0.20,
95% CI 0.80 to 0.40; Analysis 2.3).
Measures of lung function
Dimakou 2014 and Kaponi 2017 reported that spirometry tests
were not significantly different between groups but did not provide
further details in the abstracts.
Adverse events
Dimakou 2014 reported no clear differences between groups in
the number of participants experiencing adverse events (OR 2.67,
95% CI 0.36 to 19.71; Analysis 2.4) after four weeks of nebulised
treatment.
Deaths
All randomised participants completed the Dimakou 2014 study;
we therefore concluded that no deaths occurred during this trial.
Kaponi 2017 did not explicitly report deaths, and we were not
able to infer this outcome because study authors did not report
the number of participants who reached the end of the study.
Based on the overall study, we graded the quality of this evidence
as very low.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Polymyxins compared to aminoglycosides for bronchiectasis: long- term studies (≥ 4 weeks)
Patient or population: adults aged 18 years and above with diagnosis of bronchiectasis
Setting: not reported
Intervention: polymyxins (Dimakou 2014: 300 mg, inhalat ion using Pari LC Plus jet nebulizer, twice daily, 4 weeks; Kaponi 2017: 300 mg, inhalat ion using Pari LC Plus jet
nebulizer, twice daily, 3 months)
Comparison: aminoglycosides (Dimakou 2014: 1 MU, inhalat ion using Pari LC Plus jet nebulizer, twice daily, 4 weeks; Kaponi 2017: 1 MU, inhalat ion using Pari LC Plus jet
nebulizer, twice daily, 3 months)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with aminoglyco-
sides
Risk with polymyxins
Exacerbat ion - - Not est imable - - Outcome not reported in
included studies
Serious adverse events 0 per 1000 0 per 1000
(0 to 0)
Not est imable 20
(1 RCT)
⊕©©©
VERY LOWa,b,c
Evidence graded on the
overall quality of the study
Response rate - im-
provement in sputum
purulence
800 per 1000 390 per 1000
(38 to 939)
OR 0.16 (0.01 to 3.85) 20
(1 RCT)
⊕©©©
VERY LOWa,b,d
Definition of improvement
not reported
Response rate - P aerug-
inosa eradicat ion
471 per 1000 554 per 1000
(242 to 826)
OR 1.40 (0.36 to 5.35) 35
(1 RCT)
⊕©©©
VERY LOWa,b,d
Head-to-head comparison
not reported directly
Deaths 0 per 1000 0 per 1000
(0 to 0)
Not est imable 20
(1 RCT)
⊕©©©
VERY LOWa,b,c
No deaths reported. Evi-
dence graded on the overall
quality of the study
Quality of lif e - - Not est imable - - Outcome not reported in
included studies
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; P aeruginosa: Pseudomonas aeruginosa; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOne point deducted in relat ion to design and implementat ion of available studies suggest ing likelihood of bias (all study
methods unclear).
bOne point deducted for indirectness (no direct head-to-head comparisons).
cOne point deducted for imprecision (small sample size and few events).
dOne point deducted for imprecision (wide conf idence intervals).
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D I S C U S S I O N
Summary of main results
Four randomised trialsmet the inclusion criteria for this systematic
review (Chan 1996; Dimakou 2014; Kaponi 2017; Lam 1989).
All four studies included adults with a diagnosis of bronchiecta-
sis. Two trials with a total of 83 participants were conducted at
a single centre in Hong Kong and assessed the effectiveness of
fluoroquinolones compared with amoxicillin administered orally
for ten and seven days, respectively (Chan 1996; Lam 1989). The
Dimakou 2014 and Kaponi 2017 trials were available only as con-
ference abstracts and compared nebulised polymyxins (colistin)
versus nebulised aminoglycosides (tobramycin) in 55 adults for
four weeks and three months, respectively.
None of the included studies reported our primary outcome - ex-
acerbations.No serious adverse events and no deaths were reported
in any of the included studies, but we considered the quality of
this evidence to be low or very low. Two studies compared oral
amoxicillin with oral fluoroquinolones; Chan 1996 used ciproflo-
xacin and Lam 1989 used ofloxacin. Treatment failure rates were
lower with fluoroquinolones than with amoxicillin, but this find-
ing was based on low-quality evidence, leading to uncertainty in
the results. Researchers found no evidence of differences between
groups in sputum purulence (two studies) nor relapse in sputum
purulence during follow-up (one study), although again this was
based on evidence of low or very low quality. We found limited
evidence of reduced sputum volume with fluoroquinolones, but
this was based largely on one study (Chan 1996), with limited
data available from the other study. Microbiological response re-
ported in one study showed greater elimination of infective organ-
isms with ciprofloxacin, but again this finding was based on low-
quality evidence. Evidence from one study shows no differences
in lung function. The included studies did not report the number
of participants who had an adverse event.
Two studies comparing polymyxins with aminoglycosides did not
demonstrate differences between groups in terms of microbiolog-
ical response, improvement in sputum purulence or volume, or
adverse events, and data on lung function provided in the abstracts
were insufficient to inform clear conclusions. Only 55 participants
contributed to the effect estimates in this comparison, and we
judged the evidence to be of very low quality.
The wide confidence intervals and low- or very low-quality evi-
dence contribute to overall uncertainty in the results.
None of the included studies reported our other secondary out-
comes - systemic markers of infection, emergence of resistance to
antibiotics, exercise capacity, and quality of life.
Overall completeness and applicability of
evidence
All four studies potentially suffer from methodological issues, as
the risk of bias for almost all domains was unclear. Moreover, the
studies were not adequately powered to detect clinically important
differences in treatment effects between intervention groups. The
antibiotic comparisons in this review included only two classes of
antibiotics; the comparison between fluoroquinolones and amox-
icillin included 83 adults, and the comparison between polymyx-
ins and aminoglycosides included only 55 adults. All studies were
small; two were conducted at the same centre, and settings for the
third and fourth studies were not reported.Our primary outcome -
frequency of hospitalisation due to exacerbations of bronchiectasis
- was not reported in any of the included studies, but this outcome
may be less relevant for the one-week trials conducted by Chan
1996 and Lam 1989, wherein all randomised participants had an
active chest infection that could be defined as an exacerbation.
These studies may have limited clinical relevance, as exacerbations
treated with oral antibiotics would not normally require admis-
sion to hospital. The definition of treatment failure used in Chan
1996 is of limited value, as it is based solely on a poor sputum
purulence response, and, as noted by the study authors, the extent
of baseline infection in Lam 1989 may have been influenced by
previous treatment with ampicillin. A definition of exacerbations
was not provided in the studies that compared polymyxins with
aminoglycosides. None of the studies reported our secondary out-
comes - systemic markers of infection, emergence of resistance to
antibiotics, exercise capacity, or quality of life. Some of the dif-
ferences in outcomes between groups, such as sputum volume,
were reported only as P values, which limited our opportunity to
conduct pooled data analyses. Most of the data in trial abstracts
for Dimakou 2014 and Kaponi 2017 were reported narratively or
with P values alone.
We did not identify any completed studies that included children,
although our search identified two protocols (phase 1 and phase 2)
of an ongoing head-to-head study - the BEST trial, which includes
children from Australia and New Zealand (Chang 2013). Contact
with the principal investigator confirmed that the study concluded
and the research group is currently analysing the data.
We excluded 11 head-to-head trials with mixed populations of
participants (lower respiratory conditions) that did not explicitly
provide data for bronchiectasis patients alone. We attempted to
contact four of the study authors to obtain this information, but
at the time of publication, these data were not available. We were
unable to contact the authors of seven other studies.
Quality of the evidence
The overall quality of the evidence ranged from low to very low for
outcomes included in the GRADE assessment. Data were avail-
able for only three of the five pre-specified outcomes that we had
planned to include in the summary of findings table. For the com-
parison of fluoroquinolones versus amoxicillin, we included three
outcomes for response rate from two studies, but only one study
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contributed data on microbiological response. The quality of evi-
dence for both of these outcomes was low. We downgraded qual-
ity by one level for serious design limitations owing to unclear
sequence generation and allocation concealment, and by another
level for small sample sizes with few events. Evidence for excel-
lent improvement in sputum purulence was of very low quality,
downgraded by one level for serious design limitations, one level
for wide confidence intervals, and one level for small sample size
with few events. Similarly, quality of the evidence for improve-
ment in sputum purulence for the comparison of polymyxins with
aminoglycosides was very low. Unclear reporting of the study de-
sign, indirectness of comparisons (not designed as head-to-head
trials), imprecision in the effect estimate, and small sample size
contributed to downgrading of the quality of evidence.
Potential biases in the review process
Weused a comprehensive systematic search, conducted by a highly
experienced information specialist, to identify potentially eligi-
ble studies. We searched multiple resources including electronic
databases, journals, conference proceedings, reference lists of in-
cluded studies, citations of included studies, and trial registries.
Nevertheless, we recognise the possibility of publicationbias in this
review, which could either overestimate or underestimate effects
of the intervention in terms of the different outcomes included in
this review. Trials showing no, or negative, effects are less likely to
be offered for publication, and if offered are less likely to be ac-
cepted, resulting in a biased set of data available for review. As only
a small number of studies with few participants were included for
each outcome, we were unable to assess publication bias by using
formal tests.
Furthermore, it is possible that some papers were misclassified as
not eligible for inclusion in the Review. All studies were indepen-
dently assessed by two review authors, and verified by a third, and
we are confident that studies excluded from the analyses were as-
sessed on the basis of consistent and appropriate criteria. For some
full-text reports, it is possible that data could have been incorrectly
entered into analyses, although all data were double-checked to
avoid data extraction errors.
We contacted the investigator of two of the included studies to
request further information on study characteristics and other nu-
merical outcome data, as the reports were available only as confer-
ence abstracts, but at the time of publication, we have not received
a response.
Owing to the small number of included studies, we were unable
to conduct sensitivity or subgroup analyses as planned.
Agreements and disagreements with other
studies or reviews
The EMBARC Working Group recently provided a compre-
hensive and explicit definition of pulmonary exacerbations for
bronchiectasis that includes “three or more of the following key
symptoms for at least 48 hours: cough; sputum volume and/or
consistency; sputum purulence; breathlessness and/or exercise tol-
erance; fatigue and/or malaise; haemoptysis” (Hill 2017). How-
ever, the definition of an exacerbation used as an entry criterion
in our four included studies was based on only sputum purulence
and/or sputum volume. The duration of antibiotic therapy in two
of the four included studies - Lam 1989 and Chan 1996 - could
be considered suboptimal comparedwith guideline-recommended
therapy of at least 14 days (Pasteur 2010; Polverino 2017). Al-
though evidence to inform optimal choice of antibiotic is limited,
current guidelines recommend amoxicillin, 1 g three times a day,
for those with no previous bacteriology, or clarithromycin, 500
mg twice daily, for those allergic to penicillin, as the primary treat-
ment for exacerbations (Pasteur 2010). Furthermore, high-dose
oral regimens such as amoxicillin 1 g three times a day or amox-
icillin 3 g twice daily are recommended for patients with severe
bronchiectasis chronically colonised with Haemophilus influenzae
(Pasteur 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review identified a small amount of low-quality ev-
idence favouring oral fluoroquinolones over beta-lactams based on
83 adult patients hospitalised with an exacerbation, but found no
evidence of this comparison for long-term use or with a nebulised
route of administration. Very low-quality evidence from 55 adults
suggests no benefit from long-term use of polymyxins compared
with aminoglycosides, but again we found no evidence for short-
term use or other routes of administration for this comparison.
We found no evidence for either of these comparisons in children.
Based on the limited number of studies included in this review,
evidence is insufficient to guide the choice of antibiotic therapy
for exacerbations of bronchiectasis in adults or children, although
we found no evidence of significant adverse events. Overall we
have low or very low confidence in the reported outcomes. Rec-
ommendations for the general use of antibiotics are provided in
the European guidelines for bronchiectasis (Polverino 2017).
Implications for research
In view of the remarkable paucity of evidence that met our pre-
defined inclusion criteria, there is clearly a need for sufficiently
powered high-quality trials on this topic. All four trials that met
our inclusion criteria were very small (with a combined total of just
138 participants), and none of them provided robust evidence.
Our review stresses the need for further work with adults and
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children with a diagnosis of bronchiectasis by bronchography or
high-resolution computed tomography to compare one antibiotic
versus another, administered by the same delivery method. New
trials must consider this comparison in the short term and over the
longer term.We encourage researchers to incorporate the outcome
measures pre-specified in our review, and in particular, our primary
outcome measures of exacerbation (e.g. frequency during follow-
up, time to first exacerbation) and serious adverse events,
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chan 1996
Methods Aims: to compare the effectiveness of oral amoxicillin and ciprofloxacin for treatment
of infective exacerbations of patients with bronchiectasis
Design: randomised, double-blind, placebo-controlled trial. Each arm received the active
intervention plus a dummy of the comparator intervention (i.e. double dummy)
Total study duration: not reported
Number of study centres and locations: single, Hong Kong
Study setting: hospital
Methods of recruitment: not reported
Withdrawals: no participants withdrew from the study, but amoxicillin treatment was
withdrawn from 2 participants who developed a rash
Study start and end dates: not reported
Analysis by intent-to-treat: yes
Participants 42 adults were randomised.
Inclusion criteria: hospitalised patients with an infective exacerbation of bronchiectasis,
defined by a change in sputum colour (i.e. becoming purulent) or an increase in sputum
volume
Exclusion criteria:history of hypersensitivity to study antibiotics and those on antibiotic
treatment within 2 weeks before admission
Mean age: ciprofloxacin group 1 (CG): 64.5 years; amoxicillin group (AG): 63.4 years;
range: 34 to 89 years
Gender: CG: 14 females, 7 males; AG: 13 females, 8 males
Bronchiectasis diagnosis: based on clinical and radiological criteria (Luce JM:
Bronchiectasis. In Murray JF, Nadal JA (eds): Textbook of Respiratory Medicine.
Philadelphia: Saunders, 1988, pp 1107-1125)
Definition of acute exacerbation: change in sputum colour (i.e. becoming more puru-
lent) or increase in volume of sputum
Severity of condition: All participants hadmoderate to severe airflow obstruction. Most
had chronic sputumproduction between exacerbations. Almost all participants had cystic
changes on chest radiographs
History of bronchiectasis, years (mean): CG: 12.7 years; AG: 12.5 years
Mean exacerbation episodes per participant requiring antibiotics in previous year:
CG: 4.3; AG: 3.8
Patients producing daily sputum between exacerbations (n): CG: 20; AG: 18
Baseline lung function (mean ± SD): FEV % predicted: CG: 0.69 ± 0.34; AG: 0.72
± 0.51; FEV /FVC: CG: 58.6 ± 20.6; AG: 58 ± 15.3
Smoking history: current: CG: 1; AG: 0; former: CG: 6; AG: 9; non-smoker: CG: 14;
AG: 13
Baseline imbalances: none
Interventions Treatment started on the day of admission to hospital
CG: ciprofloxacin (n = 21)
Dose: 500 mg; delivery mode: oral; frequency: twice daily; duration: 7 days
Co-intervention: amoxicillin placebo
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Chan 1996 (Continued)
AG: amoxicillin (n = 21)
Dose: 1000 mg; delivery mode: oral; frequency: 3 times daily; duration: 7 days
Co-intervention: ciprofloxacin placebo
Both groups: Other treatments such as physiotherapy and bronchodilators were pre-
scribed as required
Two participants in AG developed a rash, and treatment was stopped, although it is
unclear at what stage of treatment and whether treatment was restarted
Outcomes Temperature, sputum volume, sputum purulence, haemoptysis, dyspnoea and cough,
FEV , FVC, blood count, biochemistry
Notes Power calculation: not reported
Trial registration: not reported
Conflict of interest: not reported
Funders: Daiichi Seiyaku Co Ltd provided active and matched placebo tablets
Role of the sponsors: not reported
Ethical approval: obtained from the Chinese University of Hong Kong
Conclusions: Ciprofloxacin is an effective treatment for infective exacerbations of
bronchiectasis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded using a double-dummy
design. The appearance of active tablets of
ciprofloxacin and amoxicillin was identical
to the placebo tablets of ciprofloxacin and
amoxicillin, so that neither patients nor the
physicians responsible for treatment and
evaluationwere aware of the treatment each
individual patient was receiving
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments were made by blinded ob-
servers.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patientswere assessed at the endof treat-
ment.
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
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Chan 1996 (Continued)
Other bias Unclear risk Amoxicillinwaswithdrawn from2patients
who developed a rash, but no further details
were reported
Dimakou 2014
Methods Aims: to evaluate the effect of inhaled tobramycin (Bramitob, Chiesi) and colistimethate
sodium (Colistin, Norma) in patients with non-CF bronchiectasis andP aeruginosa in
sputum
Design: randomised, placebo-controlled trial
Total study duration: not reported
Number of study centres and locations: not reported
Study setting: not reported
Methods of recruitment: not reported
Withdrawals: not reported
Study start and end dates: not reported
Analysis by intent-to-treat: not reported
Participants 29 adults were randomised.
Inclusion criteria: non-CF bronchiectasis with > 10 CFUs of P aeruginosa/mL in
sputum culture.
Exclusion criteria: not reported
Mean age: 56.06 years; range: 24 to 80 (not reported per group)
Gender: 19 women, 10 men (not reported per group)
Bronchiectasis diagnosis: not reported
Definition of acute exacerbation: not reported
Severity of condition: not reported
Baseline lung function: not reported
Smoking history: not reported
Baseline imbalances: not reported
Interventions Tobramycin (n = 10)
Dose: 300 mg; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice
daily; duration: 4 weeks
Colistin (n = 10)
Dose: 1 MU; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice
daily; duration: 4 weeks
Saline solution (n = 9)
Dose: 0.9% 4 mL; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency:
twice daily; duration: 4 weeks
Outcomes Symptoms, sputum purulence and culture, spirometry, SaO before and after treatment
Notes Power calculation: not reported
Trial registration: not reported
Conflict of interest: not reported
Funders: not reported
Role of the sponsors: not reported
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Dimakou 2014 (Continued)
Ethical approval: not reported
Conclusions: “Data indicate that inhaled antibiotics, tobramycin and colistin may be
effective in improving symptoms and reducing P aeruginosa load in bronchiectatic pa-
tients. Further investigation is necessary”
Significance values are given for improvements over 4 weeks, and both antibiotics are
described as showing greater improvement compared with saline solution. Comparisons
between the 2 antibiotics are not reported in this conference abstract, and we were unable
to contact the study authors for further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Other bias Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
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Kaponi 2017
Methods Aims: to evaluate the effect of inhaled tobramycin and colistin on eradication of P
aeruginosa in patients with NCFB [Abstract]
Design: randomised trial
Total study duration: 3 months
Number of study centres and locations: not reported
Study setting: not reported
Methods of recruitment: not reported
Withdrawals: not reported
Study start and end dates: not reported
Analysis by intent-to-treat: not reported
Participants 52 adults were randomised.
Inclusion criteria: non-CF bronchiectasis with > 10 CFUs of P aeruginosa/mL in
sputum culture.
Exclusion criteria: not reported
Mean age: 58.6 years; standard deviation: 15.2 (not reported per group)
Gender: 33 women, 19 men (not reported per group)
Bronchiectasis diagnosis: not reported
Definition of acute exacerbation: not reported.
Severity of condition: not reported
Baseline lung function: not reported
Smoking history: not reported
Baseline imbalances: not reported
Interventions All patients received ciprofloxacin 750 mg bid for 14 days before randomisation
Tobramycin (n = 17)
Dose: 300 mg; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice
daily; duration: 3 months
Colistin (n = 18)
Dose: 1 MU; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice
daily; duration: 3 months
Saline solution (n = 17)
Dose: 0.9% 4 mL; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency:
twice daily; duration: 3 months
Outcomes Sputum culture, volume and purulence, dyspnoea (MRC scale), spirometry, and SaO
were estimated before and after treatment
Notes Power calculation: not reported
Trial registration: not reported
Conflict of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions: “Our findings indicate that inhaled antibiotics, tobramycin and colistin
may be effective in eradicating P aeruginosa, reducing bacterial load and improving
symptoms of bronchiectatic patients. Further investigation is required”
Significance values are given for improvements over 3 months, and both antibiotics
are described as showing greater improvements compared to saline solution. Direct
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Kaponi 2017 (Continued)
comparisons between the 2 antibiotics are not reported in this conference abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Other bias Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Lam 1989
Methods Aims: to compare the effectiveness of oral amoxicillin and oral ofloxacin for infective
exacerbations in non-cystic fibrosis bronchiectasis
Design: randomised, double-blind, placebo-controlled trial. Each arm received the active
intervention plus a dummy of the comparator intervention (i.e. double dummy)
Total study duration: not reported
Number of study centres and locations: single, Hong Kong
Study setting: hospital
Methods of recruitment: not reported
Withdrawals: none
Study start and end dates: not reported
Analysis by intent-to-treat: not reported
Participants 41 adults were randomised.
Inclusion criteria: hospitalised adults with an infective exacerbation of bronchiectasis,
as evidenced by sputum turning from mucoid or mucopurulent to frankly purulent
Exclusion criteria: past history of allergy to antibiotics, hepatic or renal dysfunction, or
pregnancy
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Lam 1989 (Continued)
Mean age: ofloxacin (OG): 53.1 years; range: 22 to 74; amoxicillin (AG): 52.8 years;
range: 28 to 65
Gender: OG: 9 females, 11 males; AG: 9 females, 12 males
Bronchiectasis diagnosis: in most patients (34), diagnosis of bronchiectasis was con-
firmedby clinical and radiological evidence of bronchial wall thickening or cystic changes;
in 7 patients, it was confirmed clinically and by bronchogram
Definition of acute exacerbation: sputum turning from mucoid or mucopurulent to
frankly purulent
Severity of condition: All participants had moderate to severe airflow obstruction.
Almost all participants had cystic changes on chest radiographs
History of bronchiectasis, years (mean): OG: 14.1 years; range: 3 to 60; AG: 14.7
years; range: 2 to 50
Mean episodes of exacerbations per participant in previous year requiring antibi-
otics: OG: 3.3; AG: 3.8
Sputum production daily between exacerbations (n): OG: 15; AG: 17
Baseline lung function mean (SD): FEV (L): OG: 0.97 (0.57); AG: 0.91 (0.49); FEV
(% predicted): OG: 42.1%; AG: 39.8%; FEV /FVC: OG: 59.5 (16.9); AG: 58.0 (19.
5)
Smoking history: current: OG: 2; AG: 2; former: OG: 8; AG: 9; non-smoker: OG: 10;
AG: 10
Baseline imbalances: none reported
Interventions Treatment started from the day of admission to hospital
OG: ofloxacin plus amoxicillin placebo tablets (n = 20)
Dose: 200 mg; delivery mode: oral; frequency: 3 times daily; duration: 10 days
Co-intervention: postural drainage and other prescribed treatment including bron-
chodilators as required
AG: amoxicillin plus ofloxacin placebo tablets (n = 21)
Dose: 1000 mg; delivery mode: oral; frequency: 3 times daily; duration: 10 days
Co-intervention: postural drainage and other prescribed treatment including bron-
chodilators as required
Outcomes Temperature, sputum appearance and volume, haemoptysis, cough and dyspnoea: daily
Spirometry and chest radiology: days 0 and 10
Haematological and biochemical tests, and sputum for gram smears and cultures: days
0, 5, and 10. Antibiotic levels in serum and sputum at 2 hours post dosage determined
by a disc-plate bioassay: day 5. Sputum purulence: day 10
Side effects: daily
Notes Power calculation: not reported
Trial registration: not reported
Conflict of interest: not reported
Funders: Daiichi Seiyaku Co Ltd provided the active and matched placebo tablets
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions:The role of oral ofloxacin in infective episodes of bronchiectasis appears to
be promising. It would be a useful alternative antibiotic for empirical initial treatment on
an outpatient basis. Further studies are required to define the optimal dosage ad duration
of therapy and to define its role as compared to high-dose or nebulised amoxicillin
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Lam 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were assessed at the end of
treatment.
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk’
Other bias High risk Study authors note that high levels of H
influenzae, K pneumoniae, and P aeruginosa
may be attributable to previous exposure to
ampicillin and other antibiotics
AG: amoxicillin group.
CF: cystic fibrosis.
CFUs: colony-forming units.
CG: ciprofloxacin group.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
H influenzae: Haemophilus influenzae.
K pneumoniae: Klebsiella pneumoniae.
NCFB: non cystic fibrosis bronchiectasis
OG: ofloxacin group.
P aeruginosa: Pseudomonas aeruginosa.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alberto 1968 Not a head-to-head trial of antibiotics. Comparison of mucolytic acetylcysteine vs nothing against back-
ground antibiotic therapy
Allen 1988 Not a head-to-head trial of antibiotics. Comparison of probenecid, a uricosuric agent, vs nothing against
background therapy
Begg 2000 Not restricted exclusively to patients with bronchiectasis. We endeavoured to contact the study authors to
ascertain availability of data from bronchiectasis participants, but at the time of publication of this review,
the data were unavailable
Bevilacqua 1973 Not a head-to-head trial of antibiotics. Different tetracycline doses
Bilton 2006 Not a head-to-head trial of antibiotics. Comparison of dual antibiotic vs single antibiotic alone (included
in separate review of dual antibiotics)
Bradley 2011 Intervention was not an antibiotic.
Brambilla 1992 Not restricted exclusively to patients with bronchiectasis, and no separate subgroup analysis for patients
with bronchiectasis. We endeavoured to contact the study authors to ascertain availability of data from
bronchiectasis participants, but at the time of publication of this review, the data were unavailable
Cherniack 1959 Not a randomised controlled trial
Finegold 1981 Not restricted exclusively to patients with bronchiectasis. Although distribution of initial diagnosis and
treatment response was provided in Table 2, study authors provided no data on the total number of patients
with bronchiectasis in each group. We were unable to contact the study authors for further information
Garcia-Rodriguez 1984 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Ip 1998 Not a head-to-head trial of antibiotics. Same antibiotic was administered by different delivery methods
Jia 2010 Not restricted exclusively to patients with bronchiectasis, and no separate subgroup analysis for patients
with bronchiectasis. We endeavoured to contact the study authors to ascertain availability of data from
bronchiectasis participants, but at the time of publication of this review, the data were unavailable
Khan 2003 Does not include bronchiectasis patients
Kobayashi 1984 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Kobbernagel 2016 Does not include bronchiectasis patients
Krawczyk 1981 Does not include bronchiectasis patients
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(Continued)
Lioberes 1990 Not a randomised controlled trial
Liu 2012 Not a head-to-head trial of antibiotics. Single antibiotic vs control
Mehta 1991 Not a randomised controlled trial
Nakamura 2007 Not restricted exclusively to patients with bronchiectasis. We endeavoured to contact the study authors to
ascertain availability of data from bronchiectasis participants, but at the time of publication of this review,
the data were unavailable
NCT03058718 Not a head-to-head trial. Procalcitonin-guided antibiotic therapy
NCT03093974 Not a head-to-head trial. Single antibiotic vs placebo
Pines 1964 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Pines 1967 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Pines 1981 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Ramer 1981 Not restricted exclusively to patients with bronchiectasis. We were unable to contact the study authors for
further information
Characteristics of studies awaiting assessment [ordered by study ID]
Lam 1986
Methods Aims: to compare the effectiveness of oral amoxicillin and oral ofloxacin for infective exacerbations in non-cystic
fibrosis bronchiectasis
Design: randomised, double-blind, double-dummy placebo-controlled trial
Total study duration: not reported
Number of study centres and locations: single, Hong Kong
Study setting: hospital
Methods of recruitment: not reported
Withdrawals: none
Study start and end dates: not reported
Analysis by intent-to-treat: not reported
Participants 32 adults were randomised.
Inclusion criteria: hospitalised adult patients with an infective exacerbation of bronchiectasis
Exclusion criteria: past history of allergy to antibiotics, hepatic or renal dysfunction, or pregnancy
Mean age: ofloxacin (OG): 53.6 years; range: 29 to 74; amoxicillin (AG): 54.7 years; range: 43 to 65
Gender: OG: 7 females, 8 males; AG: 7 females, 10 males
Bronchiectasis diagnosis: not reported
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Lam 1986 (Continued)
Severity of condition: not reported
History of bronchiectasis, years (mean): OG: 15.3 years; range: 3 to 60; AG: 16.2 years; range: 2 to 50
Mean episodes of exacerbations per patient in previous year requiring antibiotics: not reported
Sputum production daily between exacerbations (n): not reported
Baseline lung function mean (SD): not reported
Smoking history: current: OG: 2; AG: 2; former: OG: 5; AG: 7; non-smoker: OG: 8; AG: 8
Baseline imbalances: none reported
Interventions Treatment started from the day of admission to hospital
OG: ofloxacin plus amoxicillin placebo tablets (n = 15)
Dose: 200 mg; delivery mode: oral; frequency: 3 times daily; duration: 10 days
Co-intervention: postural drainage and other prescribed treatment including bronchodilators as required
AG: amoxicillin plus ofloxacin placebo tablets (n = 17)
Dose: 1000 mg; delivery mode: oral; frequency: 3 times daily; duration: 10 days
Co-intervention: postural drainage and other prescribed treatment including bronchodilators as required
Outcomes Temperature, sputum appearance and volume, haemoptysis, cough and dyspnoea: daily
Spirometry and chest radiology: days 0 and 10
Haematological and biochemical tests, and sputum for gram smears and cultures: days 0, 5, and 10. Antibiotic levels
in serum and sputum at 2 hours post dosage determined by a disc-plate bioassay: day 5. Sputum purulence: day 10
Notes Power calculation: 170 children (85 per arm), providing 90% power (α = 0.05, 1-sided) with 20% non-inferiority
margin to detect 80% resolution rate by day 21
Trial registration: ANZCTR; ACTRN12612000010897
Funders: Daiichi Seiyaku Co Ltd provided the active and matched placebo tablets
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions: the role of oral ofloxacin in infective episodes of bronchiectasis appears to be promising. If confirmed
in a larger number of patients, ofloxacin may prove to be a useful antimicrobial in bronchiectasis on an outpatient
basis
AG: amoxicillin group.
OG: ofloxacin group.
SD: standard deviation.
Characteristics of ongoing studies [ordered by study ID]
Chang 2013
Trial name or title BEST-2 Trial
Methods Aims: is daily oral azithromycin non-inferior (within a 20%margin) to oral amoxicillin-clavulanate in achiev-
ing resolution of exacerbations by day 21 of treatment
Design: randomised, double-blind, double-dummy, placebo-controlled trial
Total study duration: not yet published
Number of study centres and locations:multi-centre; Brisbane, Darwin, Melbourne, Perth, and Sydney in
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Chang 2013 (Continued)
Australia, and Auckland in New Zealand
Study setting: home
Methods of recruitment: chest clinic
Analysis by intent-to-treat: planned
Power calculation: 170 children (85 per arm), providing 90% power (α = 0.05, 1-sided) with 20% non-
inferiority margin to detect 80% resolution rate by day 21
Trial registration: ANZCTR; ACTRN12612000010897
Conflict of interest: Study authors declare that they have no financial competing interests related to this
study
Funders: The study is funded by a 3-year Australian NHMRC project grant (number 1019834) and is sup-
ported by a NHMRC Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander
Children grant (number 1040830). A Chang (grant number 545216) is supported by NHMRC practitioner
fellowship. KAF O’Grady is supported by funding from the Children’s Health Foundation Queensland,
Queensland Government Smart Futures fellowship (number 51008) and NHMRC Career Development
Fellowship (number 1045157)
Ethical approval:Human Research Ethics Committees of all participating institutions (Brisbane: Children’s
Health Queensland Hospital and Health Service (Royal Children’s Hospital) and University of Queensland;
Darwin: Department of Health and Families and Menzies School of Health Research; Melbourne: Royal
Children’s Hospital; Perth: Princess Margaret Hospital; Sydney: Sydney Children’s Hospital Network Human
Research ethics committee; and Auckland: Northern Ethics Committee, Ministry of Health and Starship
Children’s Health local ethics committee)
Participants Inclusion criteria: younger than 18 years; bronchiectasis, as defined by HRCT scan within the previous 5
years OR followed by a respiratory physician for treatment of bronchiectasis if diagnosed earlier; 2 or more
respiratory exacerbations of bronchiectasis symptoms in the 18 months before study enrolment
Exclusion criteria: cystic fibrosis (sweat chloride > 35 mmol/L or gene mutation); liver dysfunction; severe
(hypoxia, dyspnoea, or hospitalisation required) or recent exacerbation (in the 4weeks before study enrolment;
known hypersensitivity to macrolides or penicillins; taking regular maintenance antibiotics of the same class
as the investigational antibiotics (macrolides and penicillins); taking macrolides or penicillins within 3 weeks
of study enrolment; current or recent (within 4 months before study enrolment) identification of P aeruginosa
organism in the airways; current treatment for an oncology condition of any kind
Interventions Arm 1: daily oral azithromycin 5 mg/kg for 21 days
Arm 2: twice-daily oral amoxicillin-clavulanic acid 22.5 mg/kg for 21 days
These treatments are administered only for the first respiratory exacerbation after enrolment
Outcomes Detectable difference in PC-QOL (Parent Cough-specific Quality of Life) (minimum important difference
between groups = 0.9)
Detectable difference in serum laboratory assays: CRP, serum amyloid a, IL-6, IL-10, IP-10 (this outcome is
assessed only when possible, i.e. not in all participants)
Duration of exacerbation symptoms (symptoms of exacerbation are considered increased or changed quality
of cough, increased sputum production, or change in patient’s normal sputum colour or purulence)
Presence and prevalence of viral and bacterial respiratory pathogens and antibiotic (penicillin and macrolide)
resistance of pathogens on nasal swabs and sputum samples
Requirement for hospitalisation for respiratory exacerbations
Starting date 1/10/2012
Contact information http://www.anzctr.org.au/ACTRN12612000010897.aspx
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Chang 2013 (Continued)
Notes Status recorded as “recruitment completed”; details up-to-date on 12 June 2017
CRP: C-reactive protein.
IL: interleukin.
IP: IFN-γ -induced protein .
NHMRC: Natgional Health and Medical Research Council.
P aeruginosa: Pseudomonas aeruginosa.
PC-QOL: Patient Cough-specific Quality of Life.
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D A T A A N D A N A L Y S E S
Comparison 1. Fluoroquinolones versus β-lactam (amoxicillin)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Response rate - treatment failure 2 83 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.01, 0.32]
1.1 Ciprofloxacin 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.49]
1.2 Ofloxacin 1 41 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.77]
2 Response rate - microbiological
response: patients with
organisms eliminated
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
3 Response rate - improvement in
sputum purulence (excellent)
2 83 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [0.96, 5.72]
3.1 Ciprofloxacin vs
amoxicillin
1 42 Odds Ratio (M-H, Fixed, 95% CI) 1.5 [0.43, 5.25]
3.2 Ofloxacin vs amoxicillin 1 41 Odds Ratio (M-H, Fixed, 95% CI) 3.79 [1.03, 13.91]
4 Response rate - improvement in
sputum purulence (fair)
2 83 Odds Ratio (M-H, Fixed, 95% CI) 2.30 [0.88, 6.00]
4.1 Ciprofloxacin vs
amoxicillin
1 42 Odds Ratio (M-H, Fixed, 95% CI) 4.68 [1.17, 18.69]
4.2 Ofloxacin vs amoxicillin 1 41 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.26, 4.44]
5 Response rate - relapse of
sputum purulence at 3-month
follow-up
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Sputum volume (change mL) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 FEV1 % predicted (change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Polymyxins versus aminoglycosides
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Response rate - improvement in
sputum purulence
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Response rate - P aeruginosa
eradication
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Sputum purulence -
improvement in score at 3
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 1 Response rate -
treatment failure.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 1 Response rate - treatment failure
Study or subgroup Fluoroquinolone Amoxycillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ciprofloxacin
Chan 1996 1/21 10/21 56.2 % 0.06 [ 0.01, 0.49 ]
Subtotal (95% CI) 21 21 56.2 % 0.06 [ 0.01, 0.49 ]
Total events: 1 (Fluoroquinolone), 10 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
2 Ofloxacin
Lam 1989 1/20 8/21 43.8 % 0.09 [ 0.01, 0.77 ]
Subtotal (95% CI) 20 21 43.8 % 0.09 [ 0.01, 0.77 ]
Total events: 1 (Fluoroquinolone), 8 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Total (95% CI) 41 42 100.0 % 0.07 [ 0.01, 0.32 ]
Total events: 2 (Fluoroquinolone), 18 (Amoxycillin)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.005 0.1 1 10 200
Favours Fluoroquinolone Favours Amoxycillin
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Analysis 1.2. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 2 Response rate -
microbiological response: patients with organisms eliminated.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 2 Response rate - microbiological response: patients with organisms eliminated
Study or subgroup Fluoroquinolones Amoxycillin
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Chan 1996 8/8 2/8 20.09 [ 2.83, 142.59 ]
0.001 0.01 0.1 1 10 100 1000
Favours Amoxycillin Favours Fluoroquinolones
Analysis 1.3. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 3 Response rate -
improvement in sputum purulence (excellent).
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 3 Response rate - improvement in sputum purulence (excellent)
Study or subgroup Fluroquinolones Amoxycillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ciprofloxacin vs amoxicillin
Chan 1996 9/21 7/21 63.1 % 1.50 [ 0.43, 5.25 ]
Subtotal (95% CI) 21 21 63.1 % 1.50 [ 0.43, 5.25 ]
Total events: 9 (Fluroquinolones), 7 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Ofloxacin vs amoxicillin
Lam 1989 14/20 8/21 36.9 % 3.79 [ 1.03, 13.91 ]
Subtotal (95% CI) 20 21 36.9 % 3.79 [ 1.03, 13.91 ]
Total events: 14 (Fluroquinolones), 8 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
0.01 0.1 1 10 100
Favours Amoxycillin Favours Fluoroquinolones
(Continued . . . )
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(. . . Continued)
Study or subgroup Fluroquinolones Amoxycillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 41 42 100.0 % 2.35 [ 0.96, 5.72 ]
Total events: 23 (Fluroquinolones), 15 (Amoxycillin)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 1.88 (P = 0.061)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
0.01 0.1 1 10 100
Favours Amoxycillin Favours Fluoroquinolones
Analysis 1.4. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 4 Response rate -
improvement in sputum purulence (fair).
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 4 Response rate - improvement in sputum purulence (fair)
Study or subgroup Fluoroquinolones Amoxycillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ciprofloxacin vs amoxicillin
Chan 1996 11/21 4/21 34.2 % 4.68 [ 1.17, 18.69 ]
Subtotal (95% CI) 21 21 34.2 % 4.68 [ 1.17, 18.69 ]
Total events: 11 (Fluoroquinolones), 4 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 Ofloxacin vs amoxicillin
Lam 1989 5/20 5/21 65.8 % 1.07 [ 0.26, 4.44 ]
Subtotal (95% CI) 20 21 65.8 % 1.07 [ 0.26, 4.44 ]
Total events: 5 (Fluoroquinolones), 5 (Amoxycillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 41 42 100.0 % 2.30 [ 0.88, 6.00 ]
Total events: 16 (Fluoroquinolones), 9 (Amoxycillin)
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Chi2 = 2.12, df = 1 (P = 0.15), I2 =53%
0.01 0.1 1 10 100
Favours Amoxycillin Favours Fluoroquinolones
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Analysis 1.5. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 5 Response rate -
relapse of sputum purulence at 3-month follow-up.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 5 Response rate - relapse of sputum purulence at 3-month follow-up
Study or subgroup Fluoroquinolones Amoxycillin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lam 1989 6/19 4/13 1.04 [ 0.23, 4.77 ]
0.01 0.1 1 10 100
Favours Fluoroquinolone Favours Amoxycillin
Analysis 1.6. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 6 Sputum volume
(change mL).
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 6 Sputum volume (change mL)
Study or subgroup Fluoroquinolones Amoxycillin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chan 1996 21 -30 (9) 21 -17 (9) -13.00 [ -18.44, -7.56 ]
-20 -10 0 10 20
Favours Fluoroquinolones Favours Amoxycillin
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Analysis 1.7. Comparison 1 Fluoroquinolones versus β-lactam (amoxicillin), Outcome 7 FEV1 % predicted
(change).
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 1 Fluoroquinolones versus -lactam (amoxicillin)
Outcome: 7 FEV1 % predicted (change)
Study or subgroup Fluroquinolones Amoxycillin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lam 1989 20 14.2 (23.36) 21 16.9 (23.36) -2.70 [ -17.01, 11.61 ]
-50 -25 0 25 50
Favours Amoxycillin Favours Fluoroquinolones
Analysis 2.1. Comparison 2 Polymyxins versus aminoglycosides, Outcome 1 Response rate - improvement
in sputum purulence.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 2 Polymyxins versus aminoglycosides
Outcome: 1 Response rate - improvement in sputum purulence
Study or subgroup Aminoglycosides Polymixins Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dimakou 2014 8/10 10/10 0.16 [ 0.01, 3.85 ]
0.005 0.1 1 10 200
Favours Polymyxins Favours Aminoglycosides
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Analysis 2.2. Comparison 2 Polymyxins versus aminoglycosides, Outcome 2 Response rate - P aeruginosa
eradication.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 2 Polymyxins versus aminoglycosides
Outcome: 2 Response rate - P aeruginosa eradication
Study or subgroup Aminoglycosides Polymyxins Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaponi 2017 8/17 7/18 1.40 [ 0.36, 5.35 ]
0.1 0.2 0.5 1 2 5 10
Favours Polymyxins Favours Aminoglycosides
Analysis 2.3. Comparison 2 Polymyxins versus aminoglycosides, Outcome 3 Sputum purulence -
improvement in score at 3 months.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 2 Polymyxins versus aminoglycosides
Outcome: 3 Sputum purulence - improvement in score at 3 months
Study or subgroup Aminoglycosides Polymyxins
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaponi 2017 17 -1.3 (0.8) 18 -1.1 (1) -0.20 [ -0.80, 0.40 ]
-2 -1 0 1 2
Favours Aminoglycosides Favours Polymyxins
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Analysis 2.4. Comparison 2 Polymyxins versus aminoglycosides, Outcome 4 Adverse events.
Review: Head-to-head trials of antibiotics for bronchiectasis
Comparison: 2 Polymyxins versus aminoglycosides
Outcome: 4 Adverse events
Study or subgroup Aminoglycosides Polymyxins Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dimakou 2014 4/10 2/10 2.67 [ 0.36, 19.71 ]
0.01 0.1 1 10 100
Favours Aminoglycosides Favours Polymyxins
A D D I T I O N A L T A B L E S
Table 1. Study intervention characteristics
Study Adults/
Chil-
dren
(N)
Arm 1 Arm 2 Arm 3 Dura-
tion
Antibi-
otic (N)
Dose/
Fre-
quency
Mode of
delivery
Antibi-
otic (N)
Dose/
Fre-
quency
Mode of
delivery
Com-
parison
(N)
Dose/
Fre-
quency
Mode of
delivery
Fluoroquinolones vs β-lactams (amoxicillin)
Chan
1996
Adults
(42)
Cipro-
floxa-
cin (plus
amoxi-
cillin
placebo)
(21)
500 mg
3 times
daily
Oral Amoxi-
cillin
(plus ci-
proflo-
xacin
placebo)
(21)
1000 mg
3 times
daily
Oral - - - 7 days
Lam
1989
Adults
(41) Ofloxacin
(plus
amox-
icillin
placebo)
(20)
200 mg
3 times
daily
Oral Amoxi-
cillin
(plus
ofloxacin
placebo)
(21)
1000 mg
3 times
daily
Oral - - - 10 days
Aminoglycosides vs polymyxins
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Table 1. Study intervention characteristics (Continued)
Di-
makou
2014
Adults
(29)
To-
bramycin
(10)
300 mg
twice
daily
Inhala-
tion
by nebu-
liser
1 MU
colis-
timethate
sodium
(10)
300 mg
twice
daily
Inhala-
tion
by nebu-
liser
Saline
solution
(9)
4 mL of
0.9% so-
lution
Inhala-
tion
by nebu-
liser
4 weeks
Kaponi
2017
Adults
(52)
To-
bramycin
(17)
300 mg
twice
daily
Inhala-
tion
by nebu-
liser
1 MU
colis-
timethate
sodium
(18)
300 mg
twice
daily
Inhala-
tion
by nebu-
liser
Saline
solution
(17)
4 mL of
0.9% so-
lution
Inhala-
tion
by nebu-
liser
3
months
N: number of participants.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Search frequency
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the Cochrane Airways Trials Register
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify relevant trials from the Cochrane Airways Trials Register
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
C O N T R I B U T I O N S O F A U T H O R S
All protocol authors contributed to the Background section. SJM, SS, LF, and PM contributed to the Methods section.
ES and LF screened the searches; AK and LF extracted data and completed the risk of bias assessment; LF transferred data to Review
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S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, Other.
Funded SS to provide support for a series of reviews on bronchiectasis
External sources
• The authors declare that no external funding was received for this systematic review, Other.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aminoglycosides [∗therapeutic use]; Amoxicillin [therapeutic use]; Anti-Bacterial Agents [∗therapeutic use]; Bronchiectasis [∗drug
therapy]; Fluoroquinolones [∗therapeutic use]; Forced Expiratory Volume; Polymyxins [∗therapeutic use]; Pseudomonas Infections
[drug therapy]; Randomized Controlled Trials as Topic; beta-Lactams [∗therapeutic use]
MeSH check words
Adult; Child; Humans
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